Reducing toxicity and enhancing efficacy of doxorubicin by liposomal doxorubicin and aprepitant in breast cancer

Reducing toxicity and enhancing efficacy of doxorubicin by liposomal doxorubicin and aprepitant in breast cancer

Abstract This study investigates the efficacy and toxicity profiles of pegylated liposomal doxorubicin (Doxil) compared to conventional doxorubicin. Additionally, it evaluates the potential of combination therapy involving Doxil and doxorubicin with aprepitant, an FDA-approved agent for the manageme...

Full description

Saved in:
Bibliographic Details
Main Authors: Atefeh Ghahremanloo, Bahareh Erfani, Fereshteh Asgharzadeh, Saeide Mansoori, Fatemeh Gheybi, Seyed Isaac Hashemy
Format: Article
Language:English
Published: Nature Portfolio 2025-03-01
Series:Scientific Reports
Subjects:
Breast cancer
Doxorubicin
Aprepitant
Doxil
Cardiotoxicity
Hepatotoxicity
Online Access:https://doi.org/10.1038/s41598-025-94291-9
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41598-025-94291-9

Similar Items